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Ms. Ref. No.:  JEM-D-16-00644 
Title: Oral medication in agitation of psychiatric origin: A scoping review of randomized 
controlled trials 
 
April 3, 2017 
 
 
Dear Dr. Mills: 
 
Thank you for responding so quickly with suggestions that would make our manuscript “Oral 
medication in agitation of psychiatric origin: A scoping review of randomized controlled trials” 
more appropriate for publication in your journal.  
 
We have included your recommendations below, followed by the steps we took to revise our 
manuscript accordingly.  
 
Thank you for your sincere consideration of the editorial comments on this manuscript. You 
clearly are interested in quality care for an under-represented patient population. This 
manuscript is such a valuable work of advocacy. We need more information and you have 
demonstrated that with your work. 
 
Thank you for your understanding and support of our work. 
 
In medicine, we have learned that expert consensus is important but objective data is necessary. 
We have had some large practice errors that came out of expert consensus without data.  
 
The idea of oral anti-psychotics is good. However, in the clinical practice of Emergency 
Medicine, they may not be as safe as other options for a lot of reasons. Consider how safe it is to 
administer an oral medication to a patient who will not contract for safety. Consider the safety of 
a patient who is refusing oral medications with a staff who feels obligated to administer oral 
medication. If the oral medication is not as effective, consider the impact on the patient of 
agreeing to an oral medication then receiving an IM medication anyway. We need objective data 
to properly advocate for our patients. 
 
The editor’s point is well-taken.  The issue addressed in the current study is in fact the evidence 
base for the expert consensus, which while small, is generally supportive of the use of this route 
of medication. We have revised the manuscript to clarify that the aim of our scoping review is to 
assess the extent to which expert consensus recommendations regarding oral anti-psychotics 
have been supported by published data. This point has been made clearer in the “Objectives” 
section in the abstract, the introduction, and the discussion. 
 
For further details, please see the following manuscripts, which are provided in the references so 
that readers of the journal can reach their own conclusions regarding this matter: 
Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. Expert consensus guideline 
series: Treatment of behavioral emergencies. Postgrad Med 2001; (Spec No):1-88. 
*Detailed Response to Reviewers
 
 
 
 
 
Campillo A, Castillo E, Vilke GM, Hopper A, Ryan V, Wilson MP. First generation 
antipsychotics are still preferred in the emergency department but are often not administered 
with adjunctive medications. J Emerg Med. 2015; 49(6):901-906. 
Wilson MP, Minassian A, Bahramzi M, Campillo A, Vilke GM. Despite expert 
recommendations, second-generation antipsychotics are not often prescribed in the emergency 
department. J Emerg Med. 2014; 46(6):808-13. 
Wilson MP, Pepper D, Currier GW, Holloman GH, Feifel D. The psychopharmacology of 
agitation: Consensus statement of the American Association for Emergency Psychiatry Project 
BETA Psychopharmacology Workgroup. West JEM. 2012; 13(1):26-34. 
Gault TI, Gray SM, Vilke GM, Wilson MP. Graded Evidence-based Medicine Summaries for the 
Journal of Emergency Medicine (GEMS for JEM): Are oral medications effective in the 
management of acute agitation? J Emerg Med. 2012; 43(5):854-9. 
Please consider some subtle editorial comments below.  
 
Line 50 Please add "of presumed psychiatric origin." to this sentence. 
 
“Of presumed psychiatric origin” has been added.  
 
Line 100 "Although it has been claimed that emergency 101 physicians research common 
problems in proportion to their frequency," Please add a citation for this claim or delete it.  
 
Citation [21] has been moved to an earlier point in the sentence to avoid ambiguity.  
 
Line 107 "Recommendations for the use of 109 second-generation psychotics in reducing 
symptoms of acute agitation have therefore likely been 110 extrapolated from other data; " 
There is a lot of assumption in this sentence. Perhaps the recommendations just come from 
someone's preference or from someone's personal experience, perhaps not in an ED 
setting. Would it be more accurate to state "Recommendations for the sue of second-
generation.... have not developed out of randomized controlled trials"? Consider revising this 
statement to make it based on the facts that you have uncovered rather than on further 
conjecture.  
 
“Likely” has been removed from the sentence above to avoid conjecture and the paragraph has 
been reworded to reflect that such recommendations have been developed out of only a few 
randomized trials in addition to other non-randomized, controlled studies.  
 
Line 110: "the oral administration of SGAs to patients experiencing acute 111 agitation in the 
ED setting merits additional study." This is the crux of all of your hard work. Please make this 
an independent sentence.  
 
Agreed. This phrase above has been made an independent sentence.  
 
Line 129 "Although this recommendation may be well-advised, " please consider deleting this 
portion of the sentence. Again, assumptions are being made here.  
 
 
 
 
 
 
This sentence has been similarly revised to avoid conjecture and restate that the evidence base 
supporting the recommendations of expert consensus panels currently consists of only a small 
number of randomized, controlled trials.  
 
 
Thank you again for providing helpful feedback and please let us know if we can make further 
changes to ensure our manuscript is suitable for publication in your journal.  
 
 
Sincerely, 
 
 
Samuel Mullinax, BA 
DEMBER lab 
University of Arkansas for Medical Sciences 
Little Rock, Arkansas 
  
 
EMERGENCY MEDICINE 
200 West Arbor Drive, MC 8676     San Diego, California 92103-8676    TEL: (619) 543-6463   FAX: (619) 543-3115 
 
April 3, 2017 
 
To the editor: 
 
Thank you for considering the revisions to our manuscript “Oral medication in agitation of 
psychiatric origin: A scoping review of randomized controlled trials”. This paper aims to 
summarize the research pertaining to the use of oral second-generation psychotic medications for 
the emergent treatment of acute agitation.  We look forward to the reviewers’ comments. 
 
Sincerely, 
 
 
Samuel Mullinax, BA 
DEMBER lab 
University of Arkansas for Medical Sciences 
Little Rock, Arkansas 
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 3 
Abstract 4 
Background: Understanding more about the efficacy and safety of oral second-generation 5 
antipsychotic medications in reducing the symptoms of acute agitation could improve the 6 
treatment of psychiatric emergencies. 7 
Objectives: The objectives of this scoping review are to examine the evidence base underlying 8 
expert consensus panel recommendations for the use of oral second-generation antipsychotics to 9 
treat acute agitation in mentally ill patients. 10 
Methods:  The Cochrane Schizophrenia Group’s Study-Based Register was searched for 11 
randomized, controlled trials comparing oral second-generation antipsychotics to themselves, 12 
benzodiazepines, or first-generation antipsychotics with or without adjunctive benzodiazepines, 13 
irrespective of route of administration of the drug being compared. Six articles were included in 14 
the final review. 15 
Results: Two oral-second generation antipsychotic medications were studied across the six 16 
included trials. While the studies had relatively small sample sizes, oral second-generation 17 
antipsychotics similarly effective to IM first-generation antipsychotics in treating symptoms of 18 
acute agitation and had similar side effect profiles. 19 
Conclusions: This scoping review identified six randomized trials investigating the use of oral 20 
SGAs in the reduction of acute agitation among patients experiencing psychiatric emergencies. 21 
*Manuscript (should NOT contain any author details)
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Further research will be necessary to make clinical recommendations due to the overall dearth of 22 
randomized trials as well as the small sample sizes of the included studies. 23 
 24 
Introduction 25 
Agitated patients in the emergency department pose unique dangers to themselves and challenges 26 
for treatment providers. Although precise numbers are hard to determine, it is likely that as many 27 
as 1.7 million episodes of acute agitation are treated annually [1-2].
 
Over the past several years, 28 
expert consensus panels, most recently Project BETA, have called for improved humane 29 
practices to treat agitated patients [3]. Project BETA (“Best Evidence for the Evaluation and 30 
Treatment of Agitation”) convened over 35 experts, including emergency psychiatrists, 31 
emergency medicine physicians, and mental health clinicians, preferentially recommending 32 
second-generation antipsychotics (SGAs) over the more common combination of intramuscular 33 
haloperidol + lorazepam [4-7]. SGAs were preferentially recommended orally, both to save 34 
patients the unpleasantness of needle sticks and to potentially save injury to nursing staff but the 35 
recommendation relied mostly on expert consensus instead of a comprehensive survey of 36 
available literature [8]. 37 
A previous qualitative review on oral medications in acute agitation concluded that oral 38 
medications were at least as effective as intramuscular injections, but it included non-randomized 39 
and observational trials [9]. The objective of this study therefore was to survey the literature of 40 
randomized controlled trials on oral medications in mentally ill patients suffering from acute 41 
agitation, utilizing methodology developed by the Cochrane Collaboration, to examine the 42 
amount of evidence for the expert consensus recommendation [10-11]. 43 
 44 
Methods 45 
A scoping review aims to qualitatively summarize the research on a given topic without 46 
necessarily assessing risk of bias or synthesizing quantitative findings. Scoping reviews are 47 
particularly useful for clarifying further investigative directions, especially when the topic at 48 
hand has not been thoroughly explored in a rigorous fashion and the available evidence that does 49 
exist has been acquired through relatively heterogeneous means [12]. 50 
In this scoping paper, randomized and controlled trials were included that pertained to the use of 51 
oral second-generation psychotics in the treatment of acute agitation of presumed psychiatric 52 
origin. Trials were included if they were randomized evaluations of an oral administration of at 53 
least one second-generation antipsychotic medication (with or without other medications at same 54 
time of administration) and contained an outcome measure of acute agitation with the majority of 55 
assessments occurring within 24 hours. Trials were excluded if they were not randomized or if 56 
they did not include oral administration of second-generation antipsychotics. Furthermore, 57 
studies that switched between different medications or different routes of administration within 58 
the same group of patients without analysing the potential differences induced by such changes 59 
were excluded. Finally, records of studies with a suspected cohort of patients shared between 60 
different studies or those records with patients which were a subset or duplicate analysis of a 61 
larger patient cohort were also excluded. 62 
Identification of records  63 
The Cochrane Schizophrenia Group’s Study-Based Register was searched on March 11, 2016. 64 
This register is compiled and updated by searches of different biomedical databases, including 65 
AMED, BIOSIS, EMBASE, MEDLINE, PsycINFO, CINAHL, PubMed and registries of clinical 66 
trials. More information about this source, which contains randomized controlled clinical trials of 67 
patients with schizophrenia in addition to other severe mental illnesses, is available via 68 
http://schizophrenia.cochrane.org/register-trials. The following keywords were used: 69 
(("Oral* OR " Oral* OR *(Oral* OR *Orodispersible* OR *Tablet* OR *Pill* OR 70 
*Sublingu*OR *Sub-Lingu* OR *Sub Lingu* OR *Tongue* OR *Chew* OR 71 
*Swallow* OR *Capsule*) in Title or Abstract Field of REFERENCE OR (*(Oral)* OR 72 
*Route*) in Intervention Field of STUDY) AND ((*Aggress* OR *Violen* OR *Agitat* 73 
OR *Tranq*) in Title OR Abstract of REFERENCE OR (*Aggression* OR *Agitation* 74 
OR *Violence*) in Healthcare Condition of STUDY) 75 
After checking the relevancy of search results, the following search terms were not included 76 
among the search terms because they did not retrieve any relevant results: Capsule, Swallow, 77 
Chew, Under the Tongue, Sustained Release (SR), Extended Release (ER) (XR), and Immediate 78 
Release (IR). 79 
Data collection and processing       80 
All full records returned by the database search were inspected for relevance by [blinded for peer 81 
review]. Please see Figure 1. Multiple reports of single trials were clustered to avoid double 82 
counting. 83 
 84 
Results 85 
 Of the >20,000 randomised trials on the Cochrane Schizophrenia Group’s register (>25,000 86 
reports) only six evaluated oral antipsychotic drugs for people who are agitated or aggressive 87 
(Table 1). Trials were small (total n=465, range 20-162) and all studies generated six 88 
comparisons with only one comparison (oral risperidone vs IM haloperidol) likely to have 89 
anywhere near adequate power to adequately identify outcomes of direct clinical value (Table 2). 90 
Although all six included studies were prospective clinical trials evaluating agitated patients 91 
within 24 hours of medication administration; only two were conducted solely in the ED. 92 
Reduction in agitation was assessed using a variety of standardized rating scales; the empirically 93 
validated Positive and Negative Syndrome Scale Excited Component was used most frequently 94 
[19]. Five studies compared oral second-generation antipsychotics to IM first-generation 95 
antipsychotics or IM second-generation antipsychotics. In general, the included studies found 96 
that oral second-generation antipsychotics were effective for reducing acute agitation and had 97 
side effect profiles that were comparable to first-generation antipsychotics (Table 1).  98 
 99 
Discussion 100 
A survey of 56 medical directors of psychiatric emergency services showed a preference for the 101 
use of oral atypical antipsychotic agents [20]. Although it has been claimed that emergency 102 
physicians research common problems in proportion to their frequency [21], there is a 103 
surprisingly small amount of evidence from randomized controlled trials about the use of oral 104 
antipsychotics for acute agitation even when searching the literature for articles outside the 105 
emergency department.
 106 
Perhaps more surprising, the total number of patients randomized worldwide is only 465. Only 107 
two randomized trials have been conducted solely in an ED setting, and the only SGAs that have 108 
been studied in this manner are risperidone and olanzapine. Recommendations for the use of 109 
second-generation antipsychotics in reducing symptoms of acute agitation by expert consensus 110 
panels such as Project BETA [8] have been developed using a small number of randomized 111 
controlled trials. As noted by Gault and colleagues, however, there is more evidence when non-112 
randomized studies are included [9].
 
The oral administration of SGAs to patients experiencing 113 
acute agitation in the ED setting merits additional study.
 
114 
 115 
Limitations116 
There are important limitations of this scoping study. First, this was designed to scope out 117 
existing literature; and the risk of bias was not assessed. This survey also did not include 118 
sublingual medications and so did not capture any investigations using this formulation, although 119 
at least one such trial does exist [22]. In addition, inhaled medications were not included [23]. 120 
However, it seems unlikely that large, important, and relevant oral medication studies were 121 
missed by this methodology. 122 
Finally, this survey did not scrutinize the methodology of these articles in detail, and so the effect 123 
sizes of the interventions were not summarized. It is theoretically possible that some 124 
interventions which have a low number of participants may have nonetheless a large effect size, 125 
thus making further study unwarranted. However, even if considerable effect were reported for 126 
any one of the ten possible comparisons within the six trials, selecting a treatment based on the 127 
findings of one study is often ill-advised. 128 
 129 
Conclusions 130 
Expert consensus panels such as Allen et al and the BETA project [4,9] have preferentially 131 
recommended oral administration of SGAs for acute agitation in the ED. Although the existing 132 
evidence has generally supported the use of oral medication thus far, the available research is 133 
limited. Only six small randomized trials investigating the use of oral SGAs among patients with 134 
mental illnesses have been undertaken worldwide, and only two of those trials have taken place 135 
entirely in an ED. Further study of this issue is needed. 136 
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Article Summary 219 
1. Why is this topic important? 220 
Patients experiencing an episode of acute agitation pose risks to themselves and staff, 221 
distress other patients, and consume ED resources until they are sedated. This topic is 222 
important because it explores treatment approaches for rapidly and humanely managing 223 
agitation among mentally ill patients in an acute setting.  224 
2. What does this study attempt to show? 225 
This study summarizes existing literature pertaining to the use of oral second-generation 226 
antipsychotics in the treatment of acute agitated patients with psychiatric conditions and 227 
suggests directions for future research. 228 
3. What are the key findings? 229 
Oral second-generation antipsychotics were found to be similarly effective to IM first-230 
generation antipsychotics with similar side effect profiles by the included trials. 231 
However, only six randomized trials with small sample sizes were included, so further 232 
research is needed before clinical recommendations can be made. 233 
4. How is patient care impacted? 234 
Patient care will not be directly impacted until this topic is studied further. If more 235 
evidence emerges supporting the use oral second-generation drugs to treat acute agitation, 236 
doing so would be in line with a recent expert consensus panel as well as patient 237 
preference; patients with schizophrenia and schizoaffective disorder surveyed about 238 
antipsychotic medication have reported that they perceive receiving oral medication as 239 
less coercive than receiving an injection [24]. 240 
Table 1: Included trials and their results 
Study 
tag 
Comparison Setting Total 
N 
Primary 
assessment 
tool(s) 
Results 
Oral Intramuscular 
Currier 
2004 
Risperidone 
(2mg) + 
lorazepam 
(2mg) 
 Haloperidol 
(4mg) + 
lorazepam 
(2mg) 
 24 sites, 
ED/inpatients 
United States 
162 Positive and 
Negative 
Syndrome 
Scale (PANSS) 
5-item acute-
agitation cluster 
Similar tolerability and 
reductions in agitation 
from 30 to 120 minutes 
Hatta 
2008* 
Risperidone 
solution 
(3mg) 
Olanzapine 
disintegrating 
tablet (10mg) 
  7 EDs 
Japan 
87 Excited 
Component for 
PANSS 
(PANSS-EC) 
Similar reductions in 
agitation from 0 to 60 
minutes; Olanzapine 
provided greater recovery 
from tachycardia 
Herrera 
2005 
Risperidone 
solution 
(10mg) +  
IM placebo  
 Haloperidol 
(10mg) + 
oral placebo 
 Inpatients, 
acute ward 
Mexico 
20 PANSS-EC and 
Brief 
Psychiatric 
Rating Scale 
(BPRS) 
Similar tolerability and 
reductions in agitation 
Hsu 
2010 
Risperidone 
solution 
(3mg) 
Olanzapine 
(10mg) 
Haloperidol 
(7.5mg) 
Olanzapine 
(10mg) 
Inpatients, 
acute ward 
Taiwan 
42 PANSS-EC Greater reductions in 
agitation from 15 to 90 
minutes with oral and IM 
olanzapine than with IM 
haloperidol 
Lim 
2010 
Risperidone 
(2mg) 
 Haloperidol 
(5mg) 
 ED/inpatients 
Korea 
124 PANSS-EC and 
Clinical Global 
Impression-
Severity of 
Illness Scale 
(CGI-S) 
Similar tolerability and 
reductions in agitation 
Veser 
2006 
Risperidone 
(2mg) 
Placebo Lorazepam 
(2mg) 
 1 ED 
United States 
30 PANSS and 
BPRS 
Similar tolerability and 
reductions in agitation 
from 30 to 90 minutes 
* Pseudorandomized study design 
Table 1
Table 2. Comparisons generated from identified studies 
Comparison Study tag Estimates of total 
number or 
participants within 
comparison 
Oral risperidone vs IM 
haloperidol 
Currier 2004, Herrera 2005, Hsu 
2010, Lim 2010 
326 
Oral risperidone vs oral placebo Veser 2006 20 
Oral risperidone vs IM 
lorazepam 
Veser 2006 20 
Oral risperidone vs oral 
olanzapine 
Hatta 2008, Hsu 2010 109 
Oral risperidone vs IM 
olanzapine 
Hsu 2010 20 
Oral placebo vs IM lorazepam Veser 2006 20 
 
Table 2
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